[1]夏子聪,赵 辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705-709.
 XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(07):705-709.
点击复制

改善经导管动脉化疗栓塞术疗效的临床及基础研究进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
32
期数:
2023年07
页码:
705-709
栏目:
综述
出版日期:
2023-07-31

文章信息/Info

Title:
Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization
作者:
夏子聪 赵 辉
Author(s):
XIA Zicong ZHAO Hui.
Department of Interventional Radiology, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province 226001, China
关键词:
【关键词】 肝细胞癌 经导管动脉化疗栓塞术 药物洗脱微球 放疗 免疫治疗靶向治疗 缺氧诱导因子1α
文献标志码:
A
摘要:
【摘要】 经导管动脉化疗栓塞术(transcatheter arterial chemoembolization, TACE)常用于中晚期肝细胞癌(HCC)的一线治疗。但是由于HCC的异质性、富血管的特点以及耐药等原因,部分患者并不能从TACE中获益。近年来,为了延长中晚期HCC患者的生存期,对于改善TACE疗效策略的研究不断推进。新的栓塞材料可以增强TACE栓塞效果延缓药物释放,联合其他综合治疗,改善TACE后异常的HCC微环境,可以减少TACE后的复发率并延长生存期。随着基础研究的深入以及基础临床转化,影响TACE疗效的相关危险因素以及应对方法被不断发现和验证。

参考文献/References:

[1] 国家卫生健康委办公厅.原发性肝癌诊疗指南(2022年版)[J].中华外科杂志, 2022, 60:273- 309.
[2] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma [J]. J Hepatol, 2018, 69: 182- 236.
[3] Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation(TACE) plus sorafenib as compared with TACE alone in patients with hepato-cellular carcinoma: TACTICS trial[J]. Gut, 2020, 69: 1492- 1501.
[4] Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21: 8165.
[5] Wen P, Chen SD, Wang JR, et al. Comparison of treatment response and survival profiles between drug- eluting bead transarterial chemoembolization and conventional transarterial chemoembolization in Chinese hepatocellular carcinoma patients: a prospective cohort study[J]. Oncol Res, 2019, 27: 583- 592.
[6] Shi Q,Liu J,Li T,et al. Comparison of DEB- TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up- to- seven criteria: a single- center propensity score matching analysis: DEB- TACE vs cTACE for HCC beyond up- to- seven criteria[J]. Clin Res Hepatol Gastroenterol, 2022,46: 101893.
[7] Kalva SP, Pectasides M, Liu R, et al. Safety and effectiveness of chemoembolization with drug- eluting beads for advanced- stage hepatocellular carcinoma[J]. Cardiovasc Intervent Radiol, 2014, 37: 381- 387.
[8] Razi M, Safiullah S, Gu J, et al. Comparison of tumor response following conventional versus drug- eluting bead transarterial chemoembolization in early- and very early- stage hepatocellular carcinoma[J]. J Interv Med, 2022, 5: 10- 14.
[9] Kim HC. Radioembolization for the treatment of hepatocellular carcinoma[J]. Clin Mol Hepatol, 2017, 23: 109- 114.
[10] Dhondt E, Lambert B, Hermie L, et al. (90)Y radioembolization versus drug- eluting bead chemoembolization for unresectable hepato- cellular carcinoma: results from the TRACE phase Ⅱ randomized controlled trial[J]. Radiology, 2022, 303: 699- 710.
[11] Biederman DM,Titano JJ,Bishay VL,et al. Radiation segment-ectomy versus TACE combined with microwave ablation for unre-sectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study[J]. Radiology, 2017, 283: 895- 905.
[12] Young LB,Kolber M,King MJ,et al. Intrahepatic flow diversion prior to segmental Yttrium- 90 radioembolization for challenging tumor vasculature[J]. J Interv Med, 2022, 5: 79- 83.
[13] 高 洁,郑小北,王红亮,等. 放射性治疗药物的发展现状与展望[J]. 同位素, 2022, 35:151- 163.
[14] Su TS, Lu HZ, Cheng T, et al. Long- term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unre-sectable hepatocellular carcinoma >5 cm[J]. BMC Cancer, 2016, 16: 834.
[15] Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma a systematic review and meta- analysis[J]. JAMA Oncol, 2015, 1: 756- 765.
[16] 朱六玲,蔡陈枫,孟 岩. TACE联合调强放疗对不可切除原发性肝癌的疗效研究[J]. 国际医学放射学杂志, 2019, 42:149- 153.
[17] Ren Y, Dong X, Chen L, et al. Combined ultrasound and CT- guided iodine- 125 seeds implantation for treatment of residual hepatocellular carcinoma located at complex sites after trans- catheter arterial chemoembolization[J]. Front Oncol, 2021, 11: 582544.
[18] 王 坤. CT引导下125I粒子植入术联合TACE术治疗原发性肝癌患者的效果[J]. 中国民康医学, 2022, 34: 32- 34.
[19] Zhao M,Wang JP,Wu PH, et al. Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma[J]. Zhonghua yi xue za zhi, 2010, 90: 2916- 2921.
[20] 刘娜娜,钱贤峰.肝动脉化疗栓塞联合射频消融术治疗原发性肝癌效果分析[J]. 医学理论与实践, 2020, 33:4104- 4106.
[21] 王文忠. TACE术+CT引导下射频消融术治疗老年原发性肝癌患者的临床研究[J]. 首都食品与医药, 2020, 27:31.
[22] Zhang YJ,Chen MS,Chen Y,et al. Long- term outcomes of trans- catheter arterial chemoembolization combined with radiofrequency ablation as an initial treatment for early- stage hepatocellular carcinoma[J]. JAMA Netw Open, 2021, 4: e2126992.
[23] Kim W,Cho SK,Shin SW,et al. Combination therapy of transarterial chemoembolization(TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy[J]. Abdom Radiol (NY), 2019, 44: 2283- 2292.
[24] Liu J, Zhang W, Lu H, et al. Drug- eluting bead trans- arterial chemoembolization combined with microwave ablation therapy vs. microwave ablation alone for early stage hepatocellular carcinoma: a preliminary investigation of clinical value[J]. J Cancer Res Clin Oncol, 2022, 148: 1781- 1788.
[25] Yuan P, Zhang Z, Kuai J. Analysis on efficacy and safety of TACE in combination with RFA and MWA in the treatment of middle and large primary hepatic carcinoma[J]. J BUON, 2019, 24: 163- 170.
[26] 李虎子,段振东,赵 成,等. TACE联合冷冻消融治疗不可切除肝癌临床疗效的meta分析[J]. 介入放射学杂志, 2021, 30:804- 813.
[27] 黄军伟,陈钦寿,潘思波. 氩氦刀冷冻消融与微波消融治疗肝癌的临床研究[J]. 中国医药指南, 2019, 17:123- 124.
[28] Sidana A. Cancer immunotherapy using tumor cryoablation[J]. Immunotherapy, 2014, 6: 85- 93.
[29] Mazzoccoli G,Miele L,Oben J,et al. Biology,epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib[J]. Curr Drug Targets, 2016, 17: 783- 799.
[30] Liu K,Min XL,Peng J,et al. The changes of HIF- 1α and VEGF expression after TACE in patients with hepatocellular carcinoma[J]. J Clin Med Res, 2016, 8: 297- 302.
[31] Xue J,Ni H,Wang F, et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy[J]. J Interv Med, 2021, 4: 105- 113.
[32] Kawamura Y, Kobayashi M, Shindoh J, et al. Lenvatinib- transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma[J]. Liver Cancer, 2020, 9: 756- 770.
[33] Flecken T, Schmidt N, Hild S, et al. Immunodominance and functional alterations of tumor- associated antigen- specific CD8+ T- cell responses in hepatocellular carcinoma[J]. Hepatology, 2014, 59: 1415- 1426.
[34] Chao J, Zhu Q,Chen D, et al. Case report: transarterial chemo- embolization in combination with tislelizumab downstages unresectable hepatocellular carcinoma followed by radical salvage resection[J]. Front Oncol, 2021, 11: 667555.
[35] Montasser A,Beaufrere A,Cauchy F,et al. Transarterial chemo- embolisation enhances programmed death- 1 and programmed death- ligand 1 expression in hepatocellular carcinoma[J]. Histopathology, 2021, 79: 36- 46.
[36] Cai M,Huang W,Huang J, et al. Transarterial chemoembolization combined with lenvatinib plus PD- 1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study[J]. Front Immunol, 2022, 13: 848387.
[37] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382: 1894- 1905.
[38] Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76: 862- 873.
[39] Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress[J]. Expert Opin Investig Drugs, 2022, 31: 379- 391.
[40] Friis T, Engel AM, Bendiksen CD, et al. Influence of levamisole and other angiogenesis inhibitors on angiogenesis and endothelial cell morphology in vitro[J]. Cancers (Basel), 2013, 5: 762- 785.
[41] Lin ZH, Jiang JR, Ma XK, et al. Prognostic value of serum HIF- 1α change following transarterial chemoembolization in hepatocellular carcinoma[J]. Clin Exp Med, 2021, 21: 109- 120.
[42] 余晨曦,滕皋军.经导管动脉化疗栓塞术抵抗研究进展[J]. 介入放射学杂志, 2017, 26: 1063- 1067.
[43] Huang M, Wang L, Chen J, et al. Regulation of COX- 2 expression and epithelial- to- mesenchymal transition by hypoxia- inducible factor- 1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery[J]. Int J Oncol, 2016, 48: 2144- 2154.
[44] Liu Q, Fan D, Adah D, et al. CRISPR/Cas9- mediated hypoxia inducible factor1alpha knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma[J]. Oncol Rep, 2018, 40: 2547- 2557.
[45] Chen M,Shu G,Lv X,et al. HIF- 2α- targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma[J]. Biomaterials, 2022, 284: 121512.
[46] Hsiao HT,Lu GL,Liu YC,et al. Effective perturbations of the amplitude, gating, and hysteresis of I(K(Dr)) caused by PT- 2385, an HIF- 2α inhibitor[J]. Membranes, 2021, 11: 636.
[47] Zhang J,Li Z,Liu L,et al. Long noncoding RNA TSLNC8 is a tumor suppressor that inactivates the interleukin- 6/STAT3 signaling pathway[J]. Hepatology, 2018, 67: 171- 187.
[48] Gai X,Zhou P,Xu M,et al. Hyperactivation of IL- 6/STAT3 pathway leaded to the poor prognosis of post- TACE HCCs by HIF- 1alpha/SNAI1 axis- induced epithelial to mesenchymal transition[J]. J Cancer, 2020, 11: 570- 582.
[49] Fako V,Martin SP,Pomyen Y,et al. Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization[J]. Int J Biol Sci, 2019, 15: 2654- 2663.
[50] Martin SP,Fako V,Dang H,et al. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepa-tocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39: 99.
[51] Chen J,Xie J,Jiang Z,et al. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase- M2[J]. Oncogene, 2011, 30: 4297- 4306.
[52] Hu J,Bao Q,Cao G,et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5- fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis[J]. Cardiovasc Intervent Radiol, 2020, 43: 996- 1005.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(07):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
 .The transformation pattern of serum аfetoprotein after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: its clinical significance [J].journal interventional radiology,2012,(07):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
 ,,et al.The factors related to the formation of arterioportal shunting in patients with hepatocellular carcinomas [J].journal interventional radiology,2012,(07):206.
[4]王惠文,刘瑞宝,刘   岩,等.原发性肝癌TACE后FAK、NFκBp65表达及意义[J].介入放射学杂志,2011,(08):621.
 WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(07):621.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ;[J].介入放射学杂志,2012,(06):469.
 SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(07):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
 LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(07):974.
[7]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
 ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(07):78.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
 PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(07):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
 LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms: recent advances in research[J].journal interventional radiology,2013,(07):520.
[10]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
 YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma: analysis of treatment interval[J].journal interventional radiology,2014,(07):769.
[11]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
 WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(07):406.
[12]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114.
 YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(07):1114.
[13]刘璐璐,邵国良,庞佩佩.磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展 [J].介入放射学杂志,2017,(08):756.
 LIU Lulu,SHAO Guoliang,PANG Peipei.Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma: recent progress in research[J].journal interventional radiology,2017,(07):756.
[14]中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J].介入放射学杂志,2018,27(12):1117.
 Chinese College of Interventionalists,Chinese Medical Doctor Association.Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J].journal interventional radiology,2018,27(07):1117.
[15]张 申,张 磊,仲斌演,等.“TACE抵抗/失败”——需要全面认识[J].介入放射学杂志,2020,29(08):743.
 ZHANG Shen,ZHANG Lei,ZHONG Binyan,et al.Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”[J].journal interventional radiology,2020,29(07):743.
[16]刘 嵘,程永德,王小林,等.中国肝细胞癌TACE治疗的历史、现状和展望 ——纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(08):743.
 LIU Rong,CHENG Yongde,WANG Xiaolin,et al.The history, status and future of transarterial chemoembolization of hepatocellular carcinoma in China: in memory of Professor Gui Lin, the founder of interventional radiology in China[J].journal interventional radiology,2022,31(07):743.
[17]陆一峰,王 祁,何忠明.构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后[J].介入放射学杂志,2023,32(12):1190.
 LU Yifeng,WANG Qi,HE Zhongming..Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE[J].journal interventional radiology,2023,32(07):1190.

备注/Memo

备注/Memo:
(收稿日期:2022- 05- 14)
(本文编辑:新 宇)
更新日期/Last Update: 2023-07-31